Please assess the completion status of the following clinical trial:

Trial Title: Ezetimibe Plus Simvastatin Versus Simvastatin in Untreated Subjects With High Cholesterol (P03435)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* \>=18 years and \<= 75 years of age~* LDL-C concentration \>= 3.3 mmol/L (130 mg/dL) to \<= 4.9 mmol/L (190 mg/dL) at baseline.~* Triglyceride concentration \<3.99 mmol/L (350 mg/dL) at baseline.~* Documented coronary heart disease (CHD), which will include one or more of the following features: documented stable angina (with evidence of ischemia on exercise testing); history of MI; history of PCI (primarily PTCA with or without stent replacement); symptomatic peripheral vascular disease; documented history of atherothrombotic cerebrovascular disease; and/or documented history of non-Q wave MI.~* Stable weight history for at least 4 weeks prior to entry into study at baseline.~* Female subjects of childbearing potential must be using an acceptable method of birth control or be surgically sterilized.~Exclusion Criteria:~* Body mass index (BMI) \>=35 kg/m\^2 at baseline.~* Subjects whose liver transaminases (ALT, AST) are \>1.5 times the upper limit of normal and with active liver diseases at baseline.~* Subjects with evidence of current myopathy (including subjects with CK\>1.5 times above the upper limit of normal) at baseline.~* Subjects with clinical laboratory tests (CBC, blood chemistries, urinalysis) outside the normal range that are clinically acceptable to the investigator at baseline.~* Subjects with Type II diabetes mellitus who are poorly controlled (HbA1c\>9%) or newly diagnosed (within 3 months) or who have had a change in anti-diabetic therapy within 3 months of baseline.~* Subjects with Type I diabetes mellitus who have not been on a stable insulin regimen for 3 months prior to baseline, or who have a recent history of repeated hypoglycaemia or unstable glycaemic control.~* Subjects who have known hypersensitivity to HMG-CoA reductase inhibitors.~* Female subjects who consume \>14 units and male subjects who consume \>21 units of alcohol per week.~* Female subjects who are pregnant or breast feeding.~* Subjects who have not observed the designated washout periods for any of the prohibited medications.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Ezetimibe + Simvastatin (Type: EXPERIMENTAL): None
- Simvastatin (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).